[{"id":"7f2b2a36-c6b8-470e-9ddb-f0be399d1289","acronym":"REGULATe","url":"https://clinicaltrials.gov/study/NCT00626483","created_at":"2021-01-18T02:19:44.667Z","updated_at":"2024-07-02T16:36:33.628Z","phase":"Phase 1","brief_title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","source_id_and_acronym":"NCT00626483 - REGULATe","lead_sponsor":"Gary Archer Ph.D.","biomarkers":" IL2RA • CD4 • IL7R • NCAM1 • ISG20","pipe":" | ","alterations":" NCAM1 expression","tags":["IL2RA • CD4 • IL7R • NCAM1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • umitrelimorgene autodencel (ITI-1000)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/24/2007","start_date":" 04/24/2007","primary_txt":" Primary completion: 07/06/2016","primary_completion_date":" 07/06/2016","study_txt":" Completion: 07/06/2016","study_completion_date":" 07/06/2016","last_update_posted":"2021-03-09"}]